Nutritional therapy for post-bariatric hypoglycemia patients is designed to mitigate fast glucose elevation following meal intake [58]
Additionally according to the previous metanalyses SGLT2 inhibitors significantly decreased the risk of primary cardiovascular outcomes throughout the spectrum of different kidney functions, including stage 4 (59, 60)
Start at the lowest dose and monitor your body's response
This finding suggests the presence of a deep compartment, which became apparent only after longer sampling intervals or higher doses
Who it fits: If GLP-1/GIP is already working but hunger persists, cagrilintide could conceptually be the satiety finisher. Cagrilintide vs
Reported benefits (per available research): Studied in animal (rodent) models for tendon, ligament, and muscle healing, with researchers attributing effects to promotion of angiogenesis and fibroblast activity (preclinical studies from a Croatian research group at the University of Zagreb, spanning several decades) Originally investigated for gastroprotective properties
